Clinical Edge Journal Scan

Mendelian randomization study supports causal association between RA and coronary atherosclerosis


 

Key clinical point: Patients with rheumatoid arthritis (RA) may be more susceptible to coronary atherosclerosis, and active intervention for RA may reduce the incidence of coronary atherosclerosis.

Major finding: Genetic predisposition to RA increased the risk for coronary atherosclerosis (odds ratio 1.0021; P < .05). However, genetic liability to coronary atherosclerosis did not increase the risk for RA (P = .06).

Study details: Findings are from a two-sample Mendelian randomization study that evaluated genetic variants associated with RA using the data of 14,361 patients and 42,923 control individuals and those associated with coronary atherosclerosis using data of 14,334 patients and 346,860 control individuals.

Disclosures: This study did not declare any specific source of funding. The authors declared no conflicts of interest.

Source: Nie Q et al. Rheumatoid arthritis and coronary atherosclerosis: A two-sample Mendelian randomization study. Front Cardiovasc Med. 2023;10:1033644 (Apr 28). Doi: 10.3389/fcvm.2023.1033644

Recommended Reading

FDA puts partial hold on investigational alopecia areata drug deuruxolitinib
MDedge Rheumatology
Normal CRP during RA flares: An ‘underappreciated, persistent phenotype’
MDedge Rheumatology
Rheumatoid arthritis linked to increased Parkinson’s risk
MDedge Rheumatology
Investigational drug peresolimab shows efficacy in patients with RA
MDedge Rheumatology
Strong link between polycyclic aromatic hydrocarbons and raised rheumatoid arthritis risk
MDedge Rheumatology
Joint damage repair: A rare phenomenon in early RA
MDedge Rheumatology
Tofacitinib withdrawal not a universal option for all patients with RA in remission
MDedge Rheumatology
Factors guiding sustained remission after withdrawal of combination therapy in RA
MDedge Rheumatology
HPV infection, HPV immunization, and RA prevalence: What is the link?
MDedge Rheumatology
No evidence to indicate significantly higher risk for cancer with JAKi vs bDMARD in RA
MDedge Rheumatology